ISRG Expands Installed Base, But Is Utilization Keeping Pace?

Intuitive Surgical (ISRG) significantly expanded its global da Vinci installed base to over 10,000 units in Q1 2025, placing 367 systems and contributing to a 17% year-over-year procedure volume increase. Despite this growth, a key tension lies in core platform utilization, which rose only 2%, significantly lagging procedure volume and raising concerns about hospital ROI post-installation, especially given flat international placements due to budget constraints. This modest per-system productivity, contrasted with competitors like Stryker reporting high utilization for its Mako systems, indicates that ISRG's sustained growth depends on improving existing system throughput rather than solely on new placements.

Analysis

Intuitive Surgical (ISRG) demonstrated robust expansion in its installed base, placing 367 da Vinci systems in Q1 2025 to surpass 10,000 units globally. This fueled a 17% year-over-year growth in procedure volume and supports a strong recurring revenue model, which now constitutes 85% of total revenues. However, a significant tension exists as the growth in core multiport system utilization was only 2%, lagging substantially behind both procedure growth and the stronger utilization gains of its SP (26%) and Ion (5%) platforms. This divergence raises questions about the return on investment for hospitals, particularly as international placements remained flat due to budget constraints in key markets like Germany and Japan. While the new da Vinci 5 shows early promise, the company's high forward P/E ratio of 64.35 and a "Value Score of D" reflect the market's need for proof that per-system productivity can accelerate. In contrast, competitor Stryker (SYK) reported record Mako installations with high utilization rates, signaling intensifying competition and a potential shift in hospital ROI expectations.

Key Decisions for Investors

• Investors should scrutinize future earnings reports for an acceleration in core da Vinci system utilization, as the current 2% growth rate is unsustainable for justifying new system placements long-term.
• The premium valuation, with a forward P/E of 64.35, warrants caution given the emerging headwinds in system utilization and flat international growth, even though it is below the company's five-year median.
• It is critical to monitor the competitive landscape, particularly Stryker's market share gains and high Mako utilization, to assess if ISRG's da Vinci 5 can establish sufficient clinical differentiation to protect its market leadership.
• Focus on the adoption trajectory of the newer SP and Ion platforms, as their higher utilization growth may represent a key offset to the maturation and lagging productivity of the core multiport systems.